PL3226895T3 - Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny - Google Patents

Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny

Info

Publication number
PL3226895T3
PL3226895T3 PL15805446T PL15805446T PL3226895T3 PL 3226895 T3 PL3226895 T3 PL 3226895T3 PL 15805446 T PL15805446 T PL 15805446T PL 15805446 T PL15805446 T PL 15805446T PL 3226895 T3 PL3226895 T3 PL 3226895T3
Authority
PL
Poland
Prior art keywords
immunoglobulins
pharmaceutical product
increased stability
stability
increased
Prior art date
Application number
PL15805446T
Other languages
English (en)
Polish (pl)
Inventor
Renzo Pedrussio
Regula Styger
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52002817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3226895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of PL3226895T3 publication Critical patent/PL3226895T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/002—Packages specially adapted therefor, e.g. packages for syringes or needles or kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B65D25/14—Linings or internal coatings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • B65D81/268—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants the absorber being enclosed in a small pack, e.g. bag, included in the package
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/30—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants by excluding light or other outside radiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mechanical Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Composite Materials (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Analytical Chemistry (AREA)
PL15805446T 2014-12-03 2015-12-03 Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny PL3226895T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196069 2014-12-03
PCT/EP2015/078482 WO2016087569A1 (en) 2014-12-03 2015-12-03 Pharmaceutical product with increased stability comprising immunoglobulins
EP15805446.0A EP3226895B1 (en) 2014-12-03 2015-12-03 Pharmaceutical product with increased stability comprising immunoglobulins

Publications (1)

Publication Number Publication Date
PL3226895T3 true PL3226895T3 (pl) 2020-12-28

Family

ID=52002817

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15805446T PL3226895T3 (pl) 2014-12-03 2015-12-03 Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny
PL20186174.7T PL3763384T3 (pl) 2014-12-03 2015-12-03 Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20186174.7T PL3763384T3 (pl) 2014-12-03 2015-12-03 Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny

Country Status (14)

Country Link
US (2) US12144861B2 (enExample)
EP (3) EP3226895B1 (enExample)
JP (1) JP6726666B2 (enExample)
KR (1) KR102745501B1 (enExample)
CN (2) CN121371151A (enExample)
AU (1) AU2015357068B2 (enExample)
CA (1) CA2968915A1 (enExample)
DK (2) DK3763384T3 (enExample)
ES (2) ES2825704T3 (enExample)
HU (2) HUE052280T2 (enExample)
MX (1) MX388043B (enExample)
PL (2) PL3226895T3 (enExample)
RU (1) RU2748841C2 (enExample)
WO (1) WO2016087569A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
CN121371151A (zh) 2014-12-03 2026-01-23 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
KR102898678B1 (ko) * 2018-05-23 2025-12-12 체에스엘 베링 아게 Cidp의 치료
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
ES2841807T5 (en) * 2018-11-30 2026-06-30 Klaus Stegemann A sterile solution with an application injector comprising a medical agent and method for producing same
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
PT4003452T (pt) 2019-07-29 2026-07-10 Regeneron Pharma Embalagem de dispositivo mdico
EP4313211A1 (en) * 2021-03-30 2024-02-07 SCHOTT Pharma Schweiz AG System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN117120125A (zh) * 2021-03-30 2023-11-24 肖特制药瑞士股份公司 用于低温储存药物组合物的系统、液体组合物、方法和用途
WO2022216985A1 (en) * 2021-04-08 2022-10-13 Genixus, Corp. Syringe prefilled with pharmaceutical fluid
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
USD1035436S1 (en) 2022-08-26 2024-07-16 Regeneron Pharmaceuticals, Inc. Packaging
USD1042107S1 (en) 2022-08-26 2024-09-17 Regeneron Pharmaceuticals, Inc. Packaging
USD1047700S1 (en) 2022-08-26 2024-10-22 Regeneron Pharmaceuticals, Inc. Packaging
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20250161658A (ko) 2023-03-29 2025-11-17 체에스엘 베링 아게 부작용과 관련된 면역글로불린을 식별하는 방법
WO2026074476A1 (en) 2024-10-02 2026-04-09 Csl Behring Ag Method of detecting autoantibodies against fc epsilon receptor i

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364792A1 (de) 1973-01-15 1974-07-18 South African Inventions Verfahren zum reinigen von gammaglobulin
JPS5420124A (en) 1977-07-14 1979-02-15 Green Cross Corp:The Preparation of gamma-globulin intravenous injection
US4186192A (en) 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
JPS5731623A (en) 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
JPS56127321A (en) 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Preparation of gamma-globulin pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS57128635A (en) 1981-01-30 1982-08-10 Morishita Seiyaku Kk Pharmaceutical preparation of gamma-globulin for venoclysis
US4360451A (en) 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4439421A (en) 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS6042336A (ja) 1983-08-18 1985-03-06 Nippon Seiyaku Kk 免疫グロブリンの製造方法
JPS60120823A (ja) 1983-12-02 1985-06-28 Green Cross Corp:The ＩｇＧ単量体
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
AU5252090A (en) 1989-04-04 1990-10-11 Eli Lilly And Company Improvements in and relating to pharmaceutical formulations
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0447585B2 (de) 1990-03-22 2003-05-07 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
JPH04346934A (ja) 1991-05-24 1992-12-02 Green Cross Corp:The γ−グロブリンの液状製剤
DE4118912C1 (enExample) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP2942412B2 (ja) 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
ATE175979T1 (de) 1993-12-27 1999-02-15 Rotkreuzstiftung Zentrallab Verfahren zur herstellung eines konzentrates von anti-d-immunoglobulin g und pharmazeutische zusammensetzung, die dieses enthält
JPH07238036A (ja) 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3765108B2 (ja) 1994-09-30 2006-04-12 三菱ウェルファーマ株式会社 静脈注射用グロブリン製剤
JPH10509948A (ja) 1994-11-16 1998-09-29 バクスター インターナショナル インコーポレイテッド Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69729880T3 (de) 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CA2251342A1 (en) 1997-10-23 1999-04-23 Yutaka Hirao Room temperature storable immunoglobulin preparation for intravenous injection
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
US7708719B2 (en) * 2001-11-02 2010-05-04 Meridian Medical Technologies, Inc. Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
WO2004084816A2 (en) 2003-03-21 2004-10-07 Progenics Pharmaceuticals, Inc. IMPROVED CD4-IgG2 FORMULATIONS
US20050075611A1 (en) * 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20060076536A1 (en) * 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
EP1767347A1 (de) * 2005-09-27 2007-03-28 Alcan Technology & Management Ltd. Deckfolie für Blisterverpackungen
US8852167B2 (en) 2005-12-01 2014-10-07 Bayer Medical Care Inc. Medical connector
WO2008039761A2 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
GB0619060D0 (en) 2006-09-27 2006-11-08 Glaxosmithkline Biolog Sa Novel process
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
GB2471726B (en) * 2009-07-10 2013-09-11 Oval Medical Technologies Ltd A pre-filled syringe including an oxygen absorber
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
FR2995213A1 (fr) * 2012-09-12 2014-03-14 Lfb Biotechnologies Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
US9248229B2 (en) * 2013-03-14 2016-02-02 Becton, Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
CA2902343C (en) * 2013-03-14 2022-08-02 Becton Dickinson France S.A.S. Injectable morphine formulations
WO2016051962A1 (ja) * 2014-10-02 2016-04-07 テルモ株式会社 タンパク質溶液製剤を収容するための医療用容器
CN121371151A (zh) 2014-12-03 2026-01-23 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品

Also Published As

Publication number Publication date
US20250025554A1 (en) 2025-01-23
EP3763384B1 (en) 2024-08-28
WO2016087569A1 (en) 2016-06-09
MX388043B (es) 2025-03-19
HUE052280T2 (hu) 2021-04-28
CN106999588A (zh) 2017-08-01
AU2015357068B2 (en) 2021-07-29
AU2015357068A1 (en) 2017-05-25
DK3763384T3 (da) 2024-09-23
EP3226895A1 (en) 2017-10-11
PL3763384T3 (pl) 2025-01-20
CA2968915A1 (en) 2016-06-09
EP4450517A2 (en) 2024-10-23
MX2017007156A (es) 2017-08-28
DK3226895T3 (da) 2020-10-19
ES2825704T3 (es) 2021-05-17
RU2748841C2 (ru) 2021-05-31
KR102745501B1 (ko) 2024-12-23
EP4450517A3 (en) 2024-12-25
RU2017119008A (ru) 2019-01-09
EP3226895B1 (en) 2020-07-22
CN121371151A (zh) 2026-01-23
US12144861B2 (en) 2024-11-19
EP3763384A1 (en) 2021-01-13
JP2017537928A (ja) 2017-12-21
RU2017119008A3 (enExample) 2019-08-01
HUE069126T2 (hu) 2025-02-28
KR20170088995A (ko) 2017-08-02
US20180264111A1 (en) 2018-09-20
ES2988823T3 (es) 2024-11-21
BR112017010442A2 (pt) 2017-12-26
JP6726666B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
HUE069126T2 (hu) Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
SG11201702299SA (en) Pharmaceutical product
GB201610184D0 (en) Product
GB201502721D0 (en) Product
GB201402277D0 (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
SI3208063T1 (sl) Plastični izdelek
GB201509055D0 (en) New product
SG11201702298VA (en) Pharmaceutical preparation
GB201522232D0 (en) Combination product
SG10201913125PA (en) Fire-stopping product
IL254419A0 (en) New pharmaceutical uses
GB201409250D0 (en) New product
GB201618090D0 (en) Product
GB201510219D0 (en) Stable biosolids-containing product
GB201505791D0 (en) Pharmaceutical packaging
GB201517632D0 (en) New product
GB201615464D0 (en) Product
GB201622001D0 (en) Product
GB201614651D0 (en) Product
GB201604619D0 (en) Product
GB201513553D0 (en) Product
GB201402745D0 (en) Product
GB201521015D0 (en) Novel pharmaceutical uses
GB201411148D0 (en) New pharmaceutical uses